XML 61 R50.htm IDEA: XBRL DOCUMENT
v3.25.3

ACQUISITIONS, COLLABORATIONS AND OTHER ARRANGEMENTS (Details) € in Millions, shares in Millions, $ in Millions | 1 Months Ended | 3 Months Ended | 9 Months Ended |  |  |
--- | --- | --- | --- | --- | --- | ---
Oct. 31, 2025 USD ($) | Jan. 31, 2025 USD ($) | Jul. 31, 2024 USD ($) | Mar. 31, 2024 USD ($) | Jan. 31, 2024 USD ($) shares | Sep. 30, 2025 USD ($) shares | Sep. 30, 2024 USD ($) | Mar. 31, 2024 USD ($) | Sep. 30, 2025 USD ($) shares | Sep. 30, 2024 USD ($) | Feb. 28, 2025 | Jan. 31, 2025 EUR (€) | Dec. 31, 2024 designee
Business Combination, Separately Recognized Transaction [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Acquired in-process research and development expenses |  |  |  |  |  | $ 170 | $ 505 |  | $ 485 | $ 4,674 |  |  |
SpinCo | Galapagos Subscription Agreement |  |  |  |  |  |  |  |  |  |  |  |  |
Business Combination, Separately Recognized Transaction [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Initial capital allocation (up to) |  | $ 2,540 |  |  |  |  |  |  |  |  |  | € 2,450 |
Ownership (as a percent) |  | 25.00% |  |  |  |  |  |  |  |  |  | 25.00% |
Galapagos | Galapagos Subscription Agreement |  |  |  |  |  |  |  |  |  |  |  |  |
Business Combination, Separately Recognized Transaction [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Ownership (as a percent) |  | 25.00% |  |  |  |  |  |  |  |  |  | 25.00% |
Arcus |  |  |  |  |  |  |  |  |  |  |  |  |
Business Combination, Separately Recognized Transaction [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Ownership (as a percent) |  |  |  |  |  |  |  |  |  |  | 30.00% |  |
Ownership interest, shares (in shares) | shares |  |  |  |  |  | 31.4 |  |  | 31.4 |  |  |  |
LEO Pharma A/S | LEO Pharma A/S Agreement |  |  |  |  |  |  |  |  |  |  |  |  |
Business Combination, Separately Recognized Transaction [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Payments to acquire in process research and development |  | $ 250 |  |  |  |  |  |  |  |  |  |  |
Additional payments (up to) |  | $ 1,500 |  |  |  |  |  |  |  |  |  |  |
Arcus |  |  |  |  |  |  |  |  |  |  |  |  |
Business Combination, Separately Recognized Transaction [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Additional interest acquired, shares (in shares) | shares |  |  |  |  | 15.2 |  |  |  |  |  |  |  |
Additional equity investment |  |  |  |  | $ 320 |  |  |  |  |  |  |  |
Option fee |  |  |  |  | 100 |  |  |  |  |  |  |  |
Number of designees | designee |  |  |  |  |  |  |  |  |  |  |  |  | 3
Arcus | Prepaid and other current assets |  |  |  |  |  |  |  |  |  |  |  |  |
Business Combination, Separately Recognized Transaction [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Additional equity investment |  |  |  |  | 233 |  |  |  |  |  |  |  |
Other (income) expense, net | Arcus |  |  |  |  |  |  |  |  |  |  |  |  |
Business Combination, Separately Recognized Transaction [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Additional equity investment, premium |  |  |  |  | $ 87 |  |  |  |  |  |  |  |
Interius BioTherapeutics | Subsequent Event |  |  |  |  |  |  |  |  |  |  |  |  |
Business Combination, Separately Recognized Transaction [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Total consideration transferred | $ 350 |  |  |  |  |  |  |  |  |  |  |  |
CymaBay |  |  |  |  |  |  |  |  |  |  |  |  |
Business Combination, Separately Recognized Transaction [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Total consideration transferred |  |  |  | $ 3,900 |  |  |  |  |  |  |  |  |
Acquired in-process research and development expenses |  |  |  |  |  |  |  | $ 3,900 |  |  |  |  |
Share-based compensation expense |  |  |  |  |  |  |  | 133 |  |  |  |  |
CymaBay | Janssen Pharmaceutica |  |  |  |  |  |  |  |  |  |  |  |  |
Business Combination, Separately Recognized Transaction [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Payment to extinguish future royalty obligation |  |  | $ 320 |  |  |  |  |  |  |  |  |  |
CymaBay | Research and development expenses |  |  |  |  |  |  |  |  |  |  |  |  |
Business Combination, Separately Recognized Transaction [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Share-based compensation expense |  |  |  |  |  |  |  | 67 |  |  |  |  |
CymaBay | Selling, general and administrative expenses |  |  |  |  |  |  |  |  |  |  |  |  |
Business Combination, Separately Recognized Transaction [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Share-based compensation expense |  |  |  |  |  |  |  | $ 67 |  |  |  |  |

X
- Definition Collaborative Arrangement, Initial Capital Allocation Upon Separation + References No definition available. + Details
Name: | gild_CollaborativeArrangementInitialCapitalAllocationUponSeparation
Namespace Prefix: | gild_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Collaborative Arrangement, Rights And Obligations, Additional Payments + References No definition available. + Details
Name: | gild_CollaborativeArrangementRightsAndObligationsAdditionalPayments
Namespace Prefix: | gild_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Equity Method Investment, Additional Interest Acquired, Shares + References No definition available. + Details
Name: | gild_EquityMethodInvestmentAdditionalInterestAcquiredShares
Namespace Prefix: | gild_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Equity Method Investment, Additional Investment + References No definition available. + Details
Name: | gild_EquityMethodInvestmentAdditionalInvestment
Namespace Prefix: | gild_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Equity Method Investment, Additional Investment, Premium + References No definition available. + Details
Name: | gild_EquityMethodInvestmentAdditionalInvestmentPremium
Namespace Prefix: | gild_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Equity Method Investment, Option Fee + References No definition available. + Details
Name: | gild_EquityMethodInvestmentOptionFee
Namespace Prefix: | gild_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Equity Method Investment, Ownership Interest, Shares + References No definition available. + Details
Name: | gild_EquityMethodInvestmentOwnershipInterestShares
Namespace Prefix: | gild_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number Of Designees On Board Of Directors + References No definition available. + Details
Name: | gild_NumberOfDesigneesOnBoardOfDirectors
Namespace Prefix: | gild_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Payments To Extinguish Future Royalty Obligation + References No definition available. + Details
Name: | gild_PaymentsToExtinguishFutureRoyaltyObligation
Namespace Prefix: | gild_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of expense for award under share-based payment arrangement. Excludes amount capitalized. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479983/718-10-S45-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.F) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details
Name: | us-gaap_AllocatedShareBasedCompensationExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 55 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479908/805-50-55-1 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480060/805-50-25-1 Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 30 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480027/805-50-30-1 Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 30 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480027/805-50-30-2 + Details
Name: | us-gaap_AssetAcquisitionConsiderationTransferred
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 805 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479328/805-10-50-8 Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 805 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 41 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479303/805-10-55-41 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479328/805-10-50-3 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2 + Details
Name: | us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3 + Details
Name: | us-gaap_EquityMethodInvestmentOwnershipPercentage
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition The cash outflows from the purchase of net carrying value allocated to in-process research and development costs and materials acquired in a business combination. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13 + Details
Name: | us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of writeoff for research and development asset acquired in transaction other than business combination or from joint venture formation or both. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2 Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476148/220-40-50-21 + Details
Name: | us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gild_SpinCoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=gild_GalapagosSubscriptionAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gild_GalapagosNVMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gild_ArcusBiosciencesIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=gild_LEOPharmaASMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=gild_LEOPharmaASAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=gild_ArcusBiosciencesIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IncomeStatementLocationAxis=us-gaap_NonoperatingIncomeExpenseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_AssetAcquisitionAxis=gild_InteriusBioTherapeuticsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_AssetAcquisitionAxis=gild_CymaBayMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=gild_JanssenPharmaceuticaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |